|Orgenesis Inc -- USA Stock|| |
USD 8.10 0.30 3.85%
Chief Scientific Officer
Prof. Sarah Ferber, Ph.D., is Chief Scientific Officer of Orgenesis Inc. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a postdoctoral fellowship at the Joslin Diabetes Lab at Harvard Medical School. Prof. Ferbers breakthrough discovery suggested that humans carry their own stemcells throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferbers lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferbers research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.
Age: 59 Executive Since 2012
Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.
The company has return on total asset (ROA)
of (20.6) %
which means that it has lost $20.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (114.75) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.01 M in liabilities with Debt to Equity (D/E) ratio of 71.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orgenesis Inc has Current Ratio of 0.31 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.
Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. Orgenesis operates under Business Services classification in USA and traded on OTC Market exchange. It employs 80 people.Orgenesis Inc (ORGS) is traded on OTC Market in USA. It is located in MARYLAND, U.S.A and employs 80 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.